Impact of CDK4/6 Inhibitors on Health-Related Quality of Life Outcomes in Patients With Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

    November 2025 in “ Journal of Managed Care & Specialty Pharmacy ”
    Takako Kiener, Kevin H. Li, Erin Chiang, Quang A. Le
    TLDR CDK4/6 inhibitors generally maintain quality of life in metastatic breast cancer patients, except for some side effects like diarrhea and hair loss.
    This systematic review and meta-analysis evaluated the impact of CDK4/6 inhibitors on health-related quality of life (HRQoL) in patients with hormone receptor positive (HR+) and HER2-negative metastatic breast cancer (MBC). The study found that treatment with CDK4/6 inhibitors generally did not worsen HRQoL, except for specific patient-reported symptoms such as diarrhea and upset due to hair loss. These findings highlight the importance of considering HRQoL impacts in healthcare decisions and treatment planning for patients with MBC using CDK4/6 inhibitors.
    Discuss this study in the Community →